It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
NEW YORK (CNNMoney.com) -- The quality and safety violations that led to the shutdown of a Tylenol plant were extremely serious, and could lead to tough action by regulators on drugmaker Johnson & Johnson.
On May 1, McNeil recalled some 50 children's versions of non-prescription drugs, including Tylenol, Motrin and Benadryl. Johnson & Johnson (JNJ, Fortune 500) has suspended production at the plant.
The FDA report listed 20 violations, which include 46 consumer complaints on the recalled products. Johnson & Johnson has not revealed details of those complaints.
However, Congress has opened an investigation into the recall, and lawmakers have given both Johnson & Johnson and the FDA a May 17 deadline to hand over details about the consumer complaints and any other FDA inspection reports on the Fort Washington facility.
On Friday, the House Committee on Oversight and Government Reform announced that it would hold a hearing on May 27 to examine the recall. The panel said it had invited J&J Chief Executive William Weldon to testify.
0:00 /4:49J&J CEO on the recall: I'm sorry
The most damning, according to Lebo, was the charge that the plant "does not maintain adequate laboratory facilities for the testing and approval (or rejection) of components of drug products."
Originally posted by slank
It ain't about the safety, it is about money & marketing monopolies.